Calgary, Alberta, Canada
September 1, 2010

SemBioSys Genetics Inc. (TSX:SBS) today announced that the United States Patent and Trade Mark Office has granted the Company U.S. patent 7,786,352 entitled "Methods for the Production of Apolipoproteins in Transgenic Plants". The granted patent claims include the methods for the expression of apolipoprotein (Apo) in plants, including Apo AI(Milano), the introduction of related chimeric nucleic acid into plant cells and producing plant cells capable of growing into mature plants which produce seeds that express apolipoprotein. This patent is key to successfully commercializing plant made and seed expressed Apo AI(Milano).

The intent of the Company's global patent strategy is to own exclusive rights to transgenic production of biosimilar drugs and novel drug candidates like Apo AI(Milano) in select plant and plant-seed lines and to be able to make such drugs in a scalable and affordable manner. In doing so, the Company believes it is rapidly becoming a highly attractive partner to large pharma partners looking to enter these markets with a differentiated and patent protected manufacturing cost structure.

"The issuance of this patent and the continuing success of our Apo AI(Milano) development strengthens the program as we advance through the partnership process with interested parties. This newly granted patent significantly enhances the value of our development and commercialization program for Apo AI(Milano), our next-generation cardiovascular drug candidate with blockbuster potential," said James Szarko, President and CEO of SemBioSys. "Apo AI(Milano) has the potential to address large unmet medical needs as an acute treatment for atherosclerosis or arterial blockage caused by plaque build-up on arterial walls, which leads to stroke and heart attacks. Our plant-seed based expression system for the production of Apo, biosimilar drugs and potentially other novel pharmaceutical drug candidates is a truly disruptive technology. It facilitates economical and scalable production of Apo for commercial development, which other drug companies have found difficult and expensive to produce using traditional fermentation methods. This newly patented process makes this drug candidate far more attractive and valuable to a potential pharmaceutical partner for commercial development."

A counterpart to the U.S. patent US 7,786,352 was issued in New Zealand and South Africa, and corresponding patents are pending in many jurisdictions worldwide including Europe, China, Japan, India, Eurasia, Brazil, Australia and Canada.

Website: http://www.sembiosys.ca

Published: September 1, 2010